CAC
ORIAW

Cowen and Company’s Orion Biotech Opportunities Corp. Warrant ORIAW Stock Holding History

Cowen and Company’s Portfolio ORIAW Stock Details ORIAW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-26,647
Closed -$10K – 809
2022
Q1 		$10K Buy
+26,647
New +$13.7K ﹤0.01% 507

Other funds holding ORIAW

RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
AGC
Angelo Gordon & Co New York $1.06B AUM 47.95% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
FTCM
Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return

Cowen and Company's ORIAW Position: Q2 2022 in Review

Cowen and Company sold out of Orion Biotech Opportunities Corp. Warrant (ORIAW) in Q2 2022, closing a stake of 26,647 shares — an estimated $10K sold.

Cowen and Company first reported a position in ORIAW in Q1 2022 and held it in 1 quarter. The position peaked at $10K in Q1 2022. 29 funds tracked by Wall St. Rank hold ORIAW as of Q2 2022.

  • Cowen and Company reported no remaining Orion Biotech Opportunities Corp. Warrant position as of Q2 2022 after selling out during the quarter.
  • Cowen and Company sold 26,647 Orion Biotech Opportunities Corp. Warrant shares in Q2 2022, an estimated $10K.
  • Cowen and Company first reported a position in Orion Biotech Opportunities Corp. Warrant in Q1 2022 and held it in 1 quarter.
  • Cowen and Company's Orion Biotech Opportunities Corp. Warrant position peaked at $10K in Q1 2022.
  • 29 funds tracked by Wall St. Rank held Orion Biotech Opportunities Corp. Warrant as of Q2 2022.

Based on Cowen and Company's 13F filing for Q2 2022, filed 5 Aug 2022.